Bladder cancer updates from the first half of 2024
Bladder cancer updates from the first half of 2024
Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
Updates from ASCO 2024 in gastrointestinal tumours
Hormonal receptor positive breast cancer adjuvant and metastatic indications
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer
Administering systemic chemotherapy improves survival for patients with resectable CRCLM
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ASCO 2024: Lung cancer highlights
ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia
Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM